Esperion Therapeutics | ESPR - PE Price to Earnings


Esperion Therapeutics reported 129.79 in PE Price to Earnings for its fiscal quarter ending in December of 2024.





Pe Change Date
AbbVie 23.03 1 Mar/2026
Alnylam Pharmaceuticals 80.04 90.66 Mar/2026
Amarin 91.05 88.3 Jun/2023
Amgen 19.84 5.47 Mar/2026
Biogen 13.7 0.32 Mar/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Cipla 23.56 4.18 Mar/2026
CSL 16.16 9.59 Dec/2025
Daiichi Sankyo 20.73 1.74 Dec/2025
Eli Lilly 40.27 0.06 Mar/2026
Esperion Therapeutics 129.79 129 Dec/2024
Grifols 11.2 1.08 Dec/2025
Halozyme Therapeutics 11.35 11.8 Mar/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Merck 16.52 2.6 Mar/2026
Moderna 27.22 14.51 Jun/2023
Pfizer 9.32 5.16 Mar/2026
PTC Therapeutics 9.98 3.25 Dec/2025
Puma Biotechnology 13.93 44.88 Jun/2024
Regeneron Pharmaceuticals 25.14 7.03 Mar/2026
Sanofi 11.84 0.14 Mar/2026
Sarepta Therapeutics 27.27 0 Dec/2025
United Therapeutics 20.42 3.1 Mar/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023